NEWXXITEK™HVT+ND

Get a Head Start With Early Immunity.

NEWXXITEK™ HVT+ND is an HVT-vectored vaccine with a live Marek's disease serotype 3, containing a gene insert from a Newcastle disease virus.

  • NEWXXITEK HVT+ND is an HVT-vectored vaccine
  • Contains an F gene insert from the Texas velogenic strain of NDV
  • Developed using the same technology and expertise as VAXXITEK® HVT+IBD

Key Advantages

  • HVT vector containing the F gene from the Texas velogenic strain of NDV
  • Same insertion site and promoter as VAXXITEK HVT+IBD
  • Clinical protection detected as early as two weeks after vaccination1
  • Aids in the prevention of both Marek’s (equivalent to HVT) and Newcastle diseases
  • Convenient hatchery administration by subcutaneous or by in ovo vaccination
  • As safe as HVT vaccines with no live ND vaccine reaction
  • No interference with maternal antibodies
  • Seroconversion and clinical protection were detected as early as two weeks after NEWXXITEK HVT+ND vaccination1
  • Clinical protection reached 100% at 28 days of age2,3 
  • Package in 4 x 4,000 dose ampules in frozen presentation
  • Do not mix with other products, except as specified on the label
  • In case of human exposure, contact a physician
  • Administer only as recommended
  • Use entire contents when first opened
  • Do not vaccinate within 21 days before slaughter
  • Contains penicillin and streptomycin sulfate which are added as bacteriostatic agents
  • Contains Amphotericin B as a fungistatic agent
  • Inactivate unused contents before disposal

NEWXXITEK References

  1. Data on file at Boehringer Ingelheim.
  2. Data on file at Boehringer Ingelheim.
  3. Data on file at Boehringer Ingelheim.
  4. Data on file at Boehringer Ingelheim.

 

NEWXXITEK™ is a trademark of Boehringer Ingelheim Animal Health USA Inc.
POU-0046-POUL0219

Product Resources

Contact Information

  • Boehringer Ingelheim Animal Health USA Inc.

    Poultry Business Unit

    3239 Satellite Blvd.
    Duluth, GA 30096